PAP + HPV Co-Testing Increases Cevical Cancer Detection
Recent developments in cervical cancer screening, including the approval of a DNA-based HPV test as a stand-alone method for screening, has stirred debate on whether the Pap test should remain part of frontline cervical cancer screening.
PAP + HPV Co-Testing Increases Cevical Cancer Detection
Historically, the Papanicolaou (Pap) test was one of the most powerful weapons primarily responsible for the dramatic reduction in cervical cancer in the twentieth century. By the beginning of the twenty-first century, the combined use of Pap tests and high-risk human papillomavirus virus (HPV) based molecular assays contributed to a steady decline in the incidence of cervical cancer. However, recent developments in cervical cancer screening, including the approval of a DNA-based HPV test as a stand-alone method for screening, has stirred debate on whether the Pap test should remain part of frontline cervical cancer screening.
EHR-based models show promise in predicting postpartum depression
December 24th 2024Recent research published highlights the potential of electronic health record data to improve postpartum depression diagnosis, offering a step toward better mental health outcomes for birthing parents.
Read More
Midlife sexual health boosts for nonheterosexual women reported
December 23rd 2024A recent study highlights improved sexual function and reduced distress among nonheterosexual women during menopause compared to their heterosexual counterparts, shedding light on how sexual identity impacts well-being.
Read More
